Drug Profile
Research programme: antibody-drug conjugates - Genmab/Seagen
Alternative Names: HuMax-CD74-ADCLatest Information Update: 18 Dec 2023
Price :
$50
*
At a glance
- Originator Genmab; Seattle Genetics
- Developer Genmab; Seagen
- Class Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Axl receptor tyrosine kinase inhibitors; Immunomodulators; Mitosis inhibitors; Neoplasm protein inhibitors; Thromboplastin inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Solid tumours